Answers are grounded in this paper and cite their sources.
Case series reveals autoantibodies in minimal change disease, suggesting rituximab may benefit treatment-resistant patients.
Anti-nephrin autoantibodies have been detected in a subgroup of patients with MCD supporting the autoimmune etiology of the disease. Targeted anti-B-cell therapy with rituximab is an additional therapeutic option in patients with relapsing or treatment-resistant disease, or drug-related adverse effects to standard therapy.
No takes yet. Share an insight, caveat, or question.
Knehtl et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: